|
US7393682B1
(en)
*
|
1993-03-19 |
2008-07-01 |
The Johns Hopkins University School Of Medicine |
Polynucleotides encoding promyostatin polypeptides
|
|
EP0733109B9
(en)
|
1993-12-07 |
2006-07-05 |
Genetics Institute, LLC |
Bmp-12, bmp-13 and tendon-inducing compositions thereof
|
|
US6656475B1
(en)
*
|
1997-08-01 |
2003-12-02 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
|
|
US6891082B2
(en)
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
|
US7037501B2
(en)
|
2001-01-04 |
2006-05-02 |
Regents Of The University Of Minnesota |
Myostatin immnoconjugate
|
|
EP1790726B1
(en)
*
|
2001-02-08 |
2013-07-03 |
Wyeth LLC |
Modified and stabilized GDF propeptides and uses thereof
|
|
TWI329129B
(en)
*
|
2001-02-08 |
2010-08-21 |
Wyeth Corp |
Modified and stabilized gdf propeptides and uses thereof
|
|
US7629317B2
(en)
|
2001-03-29 |
2009-12-08 |
The University Of Chicago |
Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
|
|
US6734289B2
(en)
|
2001-03-29 |
2004-05-11 |
The University Of Chicago |
Gastrokines and derived peptides including inhibitors
|
|
EP1404428B1
(en)
*
|
2001-06-05 |
2006-07-19 |
Genetics Institute, LLC |
Methods for purifying highly anionic proteins
|
|
CA2453189A1
(en)
*
|
2001-07-11 |
2003-01-23 |
Ovita Limited |
Bioassay for myostatin
|
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
|
PL374966A1
(en)
|
2002-02-21 |
2005-11-14 |
Wyeth |
Follistatin domain containing proteins
|
|
BR0307907A2
(pt)
|
2002-02-21 |
2011-07-05 |
Wyeth Corp |
gasp1: proteìna contendo domìnio de folistatina
|
|
US7261893B2
(en)
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
|
AU2003301195B2
(en)
*
|
2002-12-20 |
2010-01-07 |
Amgen Inc. |
Binding agents which inhibit myostatin
|
|
WO2004108157A2
(en)
|
2003-06-02 |
2004-12-16 |
Wyeth |
Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
|
|
JP2007530055A
(ja)
|
2004-03-26 |
2007-11-01 |
アクセルロン ファーマ インコーポレーテッド |
Bmp−3プロペプチドおよび関連する方法
|
|
JP4688483B2
(ja)
|
2004-04-15 |
2011-05-25 |
株式会社テクノネットワーク四国 |
フォリスタチン変異体ポリペプチド
|
|
WO2005113590A2
(en)
|
2004-05-12 |
2005-12-01 |
Acceleron Pharma Inc. |
Bmp10 propeptides and related methods
|
|
EP1771557B1
(en)
|
2004-06-24 |
2014-12-31 |
Acceleron Pharma Inc. |
GDF3 Propeptides and Related Methods
|
|
JP2008507288A
(ja)
|
2004-07-23 |
2008-03-13 |
アクセルロン ファーマ インコーポレーテッド |
ActRII受容体ポリペプチド、方法、および組成物
|
|
BRPI0513914A
(pt)
*
|
2004-07-29 |
2008-05-20 |
Schering Plough Ltd |
uso de inibidores do alk 5 para modular ou inibir a atividade da miostatina acarretando um acréscimo maior de tecido magro em animais
|
|
EP1864139A2
(en)
*
|
2005-03-23 |
2007-12-12 |
Wyeth |
Detection of an immune response to gdf-8 modulating agents
|
|
MX2007011400A
(es)
*
|
2005-03-23 |
2007-10-11 |
Wyeth Corp |
Deteccion de agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8).
|
|
US8017576B2
(en)
|
2005-05-10 |
2011-09-13 |
The University Of Chicago |
Methods and compositions to treat mucositis
|
|
US7888486B2
(en)
|
2005-08-19 |
2011-02-15 |
Wyeth Llc |
Antagonist antibodies against GDF-8
|
|
KR101135220B1
(ko)
|
2005-10-06 |
2012-04-24 |
일라이 릴리 앤드 캄파니 |
항-마이오스타틴 항체
|
|
UA92504C2
(en)
*
|
2005-10-12 |
2010-11-10 |
Эли Лилли Энд Компани |
Anti-myostatin monoclonal antibody
|
|
US8067562B2
(en)
|
2005-11-01 |
2011-11-29 |
Amgen Inc. |
Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
|
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
|
BRPI0618947B1
(pt)
|
2005-11-23 |
2022-07-19 |
Acceleron Pharma Inc |
Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
|
|
HRP20130320T1
(en)
|
2006-09-05 |
2013-05-31 |
Eli Lilly And Company |
Anti-myostatin antibodies
|
|
CA2672758C
(en)
|
2006-12-18 |
2019-07-30 |
Acceleron Pharma Inc. |
Activin-actrii antagonists and uses for increasing red blood cell levels
|
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
|
TWI584815B
(zh)
|
2007-02-01 |
2017-06-01 |
艾瑟勒朗法瑪公司 |
活化素-ActRIIa拮抗劑及其治療或預防乳癌之用途
|
|
TW201627320A
(zh)
|
2007-02-02 |
2016-08-01 |
艾瑟勒朗法瑪公司 |
衍生自ActRIIB的變體與其用途
|
|
MX2009008510A
(es)
|
2007-02-09 |
2010-01-15 |
Acceleron Pharma Inc |
Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.
|
|
TW201718635A
(zh)
|
2007-03-06 |
2017-06-01 |
安美基公司 |
變異之活動素受體多肽及其用途
|
|
US9610327B2
(en)
|
2007-03-06 |
2017-04-04 |
Amgen Inc. |
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
|
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
|
CA2699936A1
(en)
|
2007-09-18 |
2009-03-26 |
Acceleron Pharma Inc. |
Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
|
|
KR100857861B1
(ko)
*
|
2007-10-15 |
2008-09-11 |
주식회사 바이오리더스 |
Myo-2 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
|
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
|
DK3750552T5
(da)
|
2008-08-14 |
2024-08-26 |
Acceleron Pharma Inc |
Gdf-fælder
|
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
|
PE20150680A1
(es)
|
2008-11-26 |
2015-05-16 |
Amgen Inc |
Variantes de polipeptidos receptores de activina iib y aplicaciones de estos
|
|
AU2010204985A1
(en)
|
2009-01-13 |
2011-08-04 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin
|
|
MX355042B
(es)
|
2009-06-08 |
2018-04-02 |
Acceleon Pharma Inc |
Metodos para aumentar adipositos termogenicos.
|
|
CN107267520A
(zh)
|
2009-06-12 |
2017-10-20 |
阿塞勒隆制药公司 |
截短的actriib‑fc融合蛋白
|
|
KR102170682B1
(ko)
|
2009-08-13 |
2020-10-28 |
악셀레론 파마 인코포레이티드 |
적혈구 수준을 증가시키기 위한 gdf 트랩과 에리트로포이에틴 수용체 활성인자의 병용
|
|
NZ599604A
(en)
*
|
2009-10-01 |
2014-07-25 |
Myostin Therapeutics Pty Ltd |
Synthetic myostatin peptide antagonists
|
|
EP3260130B1
(en)
|
2009-11-03 |
2021-03-10 |
Acceleron Pharma Inc. |
Methods for treating fatty liver disease
|
|
ES2658292T3
(es)
|
2009-11-17 |
2018-03-09 |
Acceleron Pharma, Inc. |
Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
|
|
CA2817008A1
(en)
|
2010-11-08 |
2012-05-18 |
Acceleron Pharma Inc. |
Actriia binding agents and uses thereof
|
|
DK3520805T3
(da)
|
2011-10-17 |
2021-04-19 |
Acceleron Pharma Inc |
Sammensætninger til behandling af myelofibrose
|
|
MY177331A
(en)
|
2012-06-15 |
2020-09-12 |
Pfizer |
Improved antagonist antibodies against gdf-8 and uses therefor
|
|
EP4678239A3
(en)
|
2012-08-01 |
2026-04-08 |
Ikaika Therapeutics, Inc. |
Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
|
|
JP6457942B2
(ja)
|
2012-10-05 |
2019-01-23 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Gdf−8阻害剤
|
|
RU2678117C2
(ru)
|
2012-11-02 |
2019-01-23 |
Селджин Корпорейшн |
Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
|
|
KR20150136061A
(ko)
|
2013-02-01 |
2015-12-04 |
산타 마리아 바이오테라퓨틱스, 인코포레이티드 |
대상에 항-액티빈-a 화합물의 투여
|
|
HRP20201914T1
(hr)
|
2013-05-06 |
2021-01-22 |
Scholar Rock, Inc. |
Sastavi i postupci za modulaciju faktora rasta
|
|
EP3131931B1
(en)
|
2014-04-18 |
2020-10-21 |
Acceleron Pharma Inc. |
Methods for increasing red blood cell levels and treating sickle-cell disease
|
|
JP6568110B2
(ja)
|
2014-06-04 |
2019-08-28 |
アクセルロン ファーマ, インコーポレイテッド |
フォリスタチンポリペプチドによる障害の処置のための方法および組成物
|
|
CN114699529A
(zh)
|
2014-06-13 |
2022-07-05 |
阿塞勒隆制药公司 |
用于治疗溃疡的方法和组合物
|
|
MA41052A
(fr)
|
2014-10-09 |
2017-08-15 |
Celgene Corp |
Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
|
|
EP3221318B1
(en)
|
2014-11-21 |
2021-08-25 |
Rigel Pharmaceuticals, Inc. |
Fused imidazole derivatives as tgf-beta inhibitors
|
|
EP3227675B1
(en)
|
2014-12-03 |
2023-03-15 |
Celgene Corporation |
Activin-actrii antagonists and uses for treating myelodysplastic syndrome
|
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
|
EP3259264B1
(en)
|
2015-02-20 |
2022-07-27 |
Rigel Pharmaceuticals, Inc. |
Gdf-8 inhibitors
|
|
JP6836998B2
(ja)
|
2015-03-02 |
2021-03-03 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
TGF−β阻害剤
|
|
US11021468B2
(en)
|
2015-04-01 |
2021-06-01 |
Rigel Pharmaceuticals, Inc. |
TGF-ß inhibitors
|
|
EP3277673B1
(en)
|
2015-04-01 |
2022-05-04 |
Rigel Pharmaceuticals, Inc. |
Tgf-beta inhibitors
|
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
|
CN113683708A
(zh)
|
2015-04-06 |
2021-11-23 |
阿塞勒隆制药公司 |
单臂i型和ii型受体融合蛋白和其用途
|
|
EP3280435B1
(en)
|
2015-04-06 |
2021-06-02 |
Acceleron Pharma Inc. |
Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
|
|
CA2983440C
(en)
|
2015-04-22 |
2024-03-12 |
Alivegen Usa Inc. |
Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
|
|
EP3370754B1
(en)
|
2015-11-04 |
2026-04-29 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating ineffective erythropoiesis
|
|
JP7072507B2
(ja)
|
2015-11-23 |
2022-05-20 |
アクセルロン ファーマ インコーポレイテッド |
眼の障害を処置するための方法
|
|
US20170306027A1
(en)
|
2016-04-06 |
2017-10-26 |
Acceleron Pharma Inc. |
Alk7 antagonists and uses thereof
|
|
AU2017296040C1
(en)
|
2016-07-15 |
2023-06-22 |
Acceleron Pharma Inc. |
Compositions and methods for treating pulmonary hypertension
|
|
LT3490582T
(lt)
|
2016-07-27 |
2024-07-25 |
Acceleron Pharma Inc. |
Kompozicijos, skirtos naudoti gydant mielofibrozę
|
|
AU2017338916B2
(en)
|
2016-10-05 |
2022-03-24 |
Acceleron Pharma Inc. |
Variant ActRIIB proteins and uses thereof
|
|
WO2018067740A1
(en)
|
2016-10-05 |
2018-04-12 |
Acceleron Pharma, Inc. |
Compositions and method for treating kidney disease
|
|
CN110678195A
(zh)
|
2016-10-05 |
2020-01-10 |
阿塞勒隆制药公司 |
ALK4:ActRIIB异多聚体及其用途
|
|
JOP20190085A1
(ar)
|
2016-10-20 |
2019-04-17 |
Biogen Ma Inc |
طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
|
|
AU2019262139A1
(en)
|
2018-05-03 |
2020-11-26 |
Acceleron Pharma Inc. |
Multispecific binders of TGFβ-superfamily ligands and uses thereof
|
|
AU2019406214A1
(en)
|
2018-12-21 |
2021-08-05 |
Northwestern University |
Use of annexins in preventing and treating muscle membrane injury
|
|
WO2020139977A1
(en)
|
2018-12-26 |
2020-07-02 |
Northwestern University |
Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
|
|
EP3995153A4
(en)
*
|
2019-06-26 |
2023-11-22 |
KNC Laboratories Co., Ltd. |
Nucleic acid drug suppressing production of myostatin gene mrna
|